What is NeuroCIM (also known as NeuroEPO)?

NeuroCIM is a genetically engineered (lab-made) version of erythropoietin (EPO). EPO is a hormone made by your kidneys that tells your bone marrow to make red blood cells. Red blood cells are important because they carry oxygen from your lungs to your brain. Standard EPO is used to treat blood issues like anemia. The research scientists in Cuba believed that an intranasal administration of EPO could benefit patients with neurological disorders - especially, Alzheimer’s disease (AD). The thought is that NeuroCIM could slow the progression of AD.

The 2017 report on the Phase I study stated that NeuroCIM is safe for humans. This was a small trial, though. There were 25 people, with 56% being women. Twenty types of adverse effects were noted. Headaches and an increase of hepatic enzymes each made up 20% of the adverse effects. The report stated that “most of the events were mild (95.5%), did not require treatment (88.6%), and were completely resolved (81.8%).”

A later study with a modified formulation called NeuroEPO Plus (NeuroCIM) had very encouraging results. This study was also conducted by the Center for Molecular Immunology, A big difference in this double-blind, randomized, placebo-controlled, Phase II-III trial is that the participants had mild to moderate AD symptoms. The participants of the earlier Phase I trial were in their 20s with no AD symptoms.

The results of the Phase II-III showed:

• More than 80% of the clinical trial participants showed their cognitive decline was stopped.

• Cognition improved in 54% of the participants.

• Over 80% of the control group (received placebo) showed worsening in their cognition.

This is an extraordinary result (if it is true). As far as I know, no drug has ever halted or reversed cognitive decline in humans.

With these astonishing results, Cuba partnered with the College of Medicine at the University of Saskatchewan for a clinical trial to test if NeuroCIM improves or maintains cognition in adults with mild to moderate AD. The drug will be administered using a cannula attached to a syringe. The participant will be positioned in a Kaiteki position. (the photos below are more or less accurate representations)

There will be 90 participants (30 placebo and 60 NeuroCIM). NeuroCIM or the placebo will be administered three times a week for 52 weeks.